Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2010 - 2023)
Lineage Cell Therapeutics (LCTX) posted quarterly Other Non-Current Assets of $552000.0 for Q3 2023, down 6.6% year-over-year from $591000.0 in Q3 2022, and down 6.12% quarter-over-quarter from $588000.0 in Q2 2023.
Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2010 - 2023) Analysis & Trends
Lineage Cell Therapeutics' Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $552000.0 for Q3 2023.
- In Q3 2023, Other Non-Current Assets fell 6.6% year-over-year to $552000.0; the TTM figure through Sep 2023 stood at $552000.0 (down 6.6% YoY), while the FY2022 annual figure was $627000.0, changed 0.48% from the prior year.
- Other Non-Current Assets for Q3 2023 stood at $552000.0, down from $588000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $890000.0 in Q1 2019, with the low at $515000.0 in Q2 2021.
- The 5-year median for Other Non-Current Assets is $614000.0 (2021), against an average of $637526.3.
- The sharpest annual moves came in 2019 and 2020: Other Non-Current Assets jumped 277.12% in 2019, then sank 37.42% in 2020.
- Lineage Cell Therapeutics' Other Non-Current Assets stood at $599000.0 in 2019, then advanced by 2.84% to $616000.0 in 2020, then climbed by 2.27% to $630000.0 in 2021, then retreated by 0.48% to $627000.0 in 2022, then decreased by 11.96% to $552000.0 in 2023.
- Business Quant data shows LCTX's Other Non-Current Assets at $552000.0 in Q3 2023, $588000.0 in Q2 2023, and $635000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 588,000.00 |
| Mar 31, 2023 | 635,000.00 |
| Dec 31, 2022 | 627,000.00 |
| Sep 30, 2022 | 591,000.00 |
| Jun 30, 2022 | 598,000.00 |
| Mar 31, 2022 | 544,000.00 |
| Dec 31, 2021 | 630,000.00 |
| Sep 30, 2021 | 614,000.00 |
| Jun 30, 2021 | 515,000.00 |
| Mar 31, 2021 | 601,000.00 |
| Dec 31, 2020 | 616,000.00 |
| Sep 30, 2020 | 666,000.00 |
| Jun 30, 2020 | 649,000.00 |
| Mar 31, 2020 | 557,000.00 |
| Dec 31, 2019 | 599,000.00 |
| Sep 30, 2019 | 826,000.00 |
| Jun 30, 2019 | 815,000.00 |
| Mar 31, 2019 | 890,000.00 |
| Dec 31, 2018 | 420,000.00 |